

Publikationen

Haense N, **Atmaca A**, Pauligk C, Steinmetz K, Marmé F, Haag GM, Rieger M, Ottmann OG, Ruf P, Lindhofer H, Al-Batran SE. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. *BMC Cancer*. 2016 Jul 7;16:420. doi: 10.1186/s12885-016-2449-0.

Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, **Atmaca A**, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol*. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4.

Atmaca A, Wirtz RW, Werner D, Steinmetz K, Claas S, Brueckl WM, Jäger E, Al-Batran SE. SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer. *BMC Cancer*. 2015 Apr 17;15:300.

Brückl WM, Al-Batran SE, Ficker JH, Wirtz RM, **Atmaca A**. Estrogen Receptors and their Impact for Prognosis and Therapy of Lung Cancer - New Insights to an Underestimated Mechanism. *Pneumologie*. 2015 Jun;69(6):350-60. Jun 11. German.

Atmaca A, Al-Batran SE, Wirtz RM, Werner D, Zirlik S, Wiest G, Eschbach C, Claas S, Hartmann A, Ficker JH, Jäger E, Brueckl WM. The validation of estrogen receptor 1 (ESR1) mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer. *Int J Cancer*. 2014 May 15;134(10):2314-21.

Atmaca A, Al-Batran SE, Allgäuer M, Jäger E. Afatinib with concurrent radiotherapy in a patient with metastatic non-small cell lung cancer. *Oncol Res Treat*. 2014;37(5):262-5.

Karbach J, Gnjatic S, Biskamp M, **Atmaca A**, Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A, Jäger E. Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. *Cancer Immunol Res*. 2014 May;2(5):404-9.

Brueckl WM, Al-Batran SE, Ficker JH, Claas S, **Atmaca A**, Hartmann A, Rieker RJ, Wirtz RM. Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. *Int J Cancer*. 2013 Oct 15;133(8):1825-31.

de Marinis F, **Atmaca A**, Tiseo M, Giuffreda L, Rossi A, Gebbia V, D'Antonio C, Dal Zotto L, Al-Batran SE, Marsoni S, Wolf M. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer. *J Thorac Oncol*. 2013 Aug;8(8):1091-4.

Werner D, **Atmaca A**, Pauligk C, Pustowka A, Jäger E, Al-Batran SE. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. *Cancer Med*. 2013 Jun;2(3):325-33.

Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, Banat AG, Brueckl P, Caca K, Prasnikar N, Kullmann F, Günther Derigs H, Koenigsmann M, Dingeldein G, Neuhaus T, Jäger E. A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. *Br J Cancer*. 2013 Feb 5;108(2):265-70.

Atmaca A, Werner D, Pauligk C, Steinmetz K, Wirtz R, Altmannsberger HM, Jäger E, Al-Batran SE. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. *BMC Cancer*. 2012 Nov 15;12:524.

Al-Batran SE, Pauligk C, Wirtz R, Werner D, Steinmetz K, Homann N, Schmalenberg H, Hofheinz RD, Hartmann JT, **Atmaca A**, Altmannsberger HM, Jäger E. The validation of matrix

metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. *Ann Oncol*. 2012 Jul;23(7):1699-705.

Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, **Atmaca A**, Noack F, Altmannsberger HM, Jäger E, Al-Batran SE. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. *Int J Cancer*. 2012 Apr 1;130(7):1706-13.

Atmaca A, Pauligk C, Steinmetz K, Altmannsberger HM, Jäger E, Al-Batran SE. Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer. *Oncology*. 2011;80(1-2):130-4.

Weidmann E, Neumann A, Fauth F, **Atmaca A**, Al-Batran SE, Pauligk C, Jäger E. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. *Ann Oncol*. 2011 Aug;22(8):1839-44.

Karbach J, Neumann A, **Atmaca A**, Wahle C, Brand K, von Boehmer L, Knuth A, Bender A, Ritter G, Old LJ, Jäger E. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. *Clin Cancer Res*. 2011 Feb 15;17(4):861-70

Neumann A, Karbach J, **Atmaca A**, Jäger E. Long-term remission of malignant melanoma stage IV after antigen-specific immunotherap. *Med Klin (Munich)*. 2010 Apr;105(4):273-5

Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, **Atmaca A**, Jäger E. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol*. 2008 Nov;19(11):1882-7.

Atmaca A, Al-Batran SE, Neumann A, Kolassa Y, Jäger D, Knuth A, Jäger E. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study. *Gynecol Oncol*. 2009 Feb;112(2):384-8.

Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, **Atmaca A**, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol*. 2008 Mar 20;26(9):1435-42.

Bender A, Karbach J, Neumann A, Jäger D, Al-Batran SE, **Atmaca A**, Weidmann E, Biskamp M, Gnjatic S, Pan L, Hoffman E, Old LJ, Knuth A, Jäger E. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. *Cancer Immun*. 2007 Oct 19;7:16.

Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzl T, Hentsch B, Schwarz SE, Hövelmann S, Göttlicher M, Knuth A, Jäger E. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. *Br J Cancer*. 2007 Jul 16;97(2):177-82.

Al-Batran SE, **Atmaca A**, Schleyer E, Pauligk C, Hosius C, Ehninger G, Jäger E. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial. *Cancer*. 2007 May 1;109(9):1897-904.

Al-Batran SE, Kerber A, **Atmaca A**, Dechow C, Reitsamer E, Schmidt S, Kolassa Y, Neumann A, Weidmann E, Hartmann JT, Jäger E. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a

salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. *Onkologie*. 2007 Feb;30(1-2):29-34.

Friedmann I, **Atmaca A**, Chow KU, Jäger E, Weidmann E. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. *J Chemother*. 2006 Aug;18(4):415-20

Al-Batran SE, Bischoff J, von Minckwitz G, **Atmaca A**, Kleeberg U, Meuthen I, Morack G, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. *Br J Cancer*. 2006 Jun 5;94(11):1615-20.

Al-Batran SE, Meerpohl HG, von Minckwitz G, **Atmaca A**, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m² every 4 weeks in previously treated patients with metastatic breast cancer. *Oncology*. 2006;70(2):141-6.

von Minckwitz G, Harder S, Hövelmann S, Jäger E, Al-Batran SE, Loibl S, **Atmaca A**, Cimpoiasu C, Neumann A, Abera A, Knuth A, Kaufmann M, Jäger D, Maurer AB, Wels WS. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. *Breast Cancer Res*. 2005;7(5):R617-26.. Erratum in: *Breast Cancer Res*. 2006;8(1):403.

Al-Batran SE, Rafiyan MR, **Atmaca A**, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. *Cancer Res*. 2005 May 1;65(9):3937-41

Al-Batran SE, **Atmaca A**, Bert F, Jäger D, Frisch C, Neumann A, Orth J, Knuth A, Jäger E. Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer. *Onkologie*. 2004 Dec;27(6):534-8

Al-Batran SE, **Atmaca A**, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. *J Clin Oncol*. 2004 Feb 15;22(4):658-63

Jäger E, Karbach J, Gnjatic S, Jäger D, Maeurer M, **Atmaca A**, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. *Cancer Immun*. 2002 Sep 19;2:12

Jäger D, Stockert E, Karbach J, Herrlinger K, **Atmaca A**, Arand M, Chen YT, Gnjatic S, Old LJ, Knuth A, Jäger E. Urine antibody against human cancer antigen NY-ESO-1. *Cancer Immun*. 2002 Aug 6;2:10